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The E-protein transcription factors guide 
immune cell differentiation, with E12 and E47 
(hereafter called E2A) being essential for B-cell 
specification and maturation. E2A and the 
oncogenic chimera E2A–PBX1 contain three 
transactivation domains (ADs), with AD1 and AD2 
having redundant, independent, and cooperative 
functions in a cell-dependent manner. AD1 and 
AD2 both mediate their functions by binding to the 
KIX domain of the histone acetyltransferase 
paralogues CREB-binding protein (CBP) and E1A-
binding protein P300 (p300). This interaction is 
necessary for B-cell maturation and oncogenesis by 
E2A–PBX1 and occurs through conserved ϕ-x-x-ϕ-
ϕ motifs (with ϕ denoting a hydrophobic amino 
acid) in AD1 and AD2. However, disruption of this 
interaction via mutation of the KIX domain in 
CBP/p300 does not completely abrogate binding of 
E2A and E2APBX1. Here, we determined that 
E2A–AD1 and E2A–AD2 also interact with the 
TAZ2 domain of CBP/p300. Characterization of 
the TAZ2:E2AAD1(1–37) complex indicated that 
E2A–AD1 adopts an α-helical structure and uses its 
ϕ-x-x-ϕ-ϕ motif to bind TAZ2. While this region 
overlapped with the KIX recognition region, key 
KIX-interacting E2A–AD1 residues were exposed, 
suggesting that E2A–AD1 could simultaneously 
bind both the KIX and TAZ2 domains. However, 
we did not detect a ternary complex involving 
E2A–AD1, KIX, and TAZ2 and found that E2A 
containing both intact AD1 and AD2 is required to 
bind to CBP/p300. Our findings highlight the 
structural plasticity and promiscuity of E2A–AD1 
and suggest that E2A binds both the TAZ2 and KIX 
domains of CBP/p300 through AD1 and AD2. 
     
The innate and adaptive immune systems rely on 
the development and differentiation of 
hematopoietic stem cells to mature blood cells, 
including B and T lymphocytes, natural killer cells, 
and plasmacytoid dendritic cells (1–3). The 
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generation of these immune cells, or 
lymphopoiesis, involves numerous intermediates, a 
progressive limitation of differentiation potential, 
and a coincident loss of the ability to self-renew (4). 
This process of lineage commitment is tightly 
regulated at the transcriptional level by complex 
regulatory networks comprising both lineage-
specific and ubiquitous transcription factors (2, 5–
7). One such set of transcription factors is the E-
protein family, which comprise class I basic helix-
loop-helix (bHLH) transcription factors that play 
essential roles in the development and specification 
of B- and T-lymphocytes (8–10). 
Members of the E-protein family include the 
alternatively spliced isoforms E12 and E47 (also 
referred to collectively as E2A), HEB, and E2-2. 
Each family member contains a C-terminal bHLH 
domain responsible for E-protein dimerization and 
binding DNA at E-box CANNTG consensus sites 
in gene enhancer and/or promoter regions (11–17). 
In addition, the E-proteins possess three conserved 
activation domains, one of which (AD1) is 
positioned at the extreme N-terminus while the 
other two (AD2 and AD3) are more centrally 
located (Fig. 1A) (14, 15, 18, 19). These activation 
domains have been shown to display cooperative, 
or independent transcriptional regulatory functions 
in a cell-specific manner (19–25). For example, 
AD1, AD2, and AD3 independently induce 
transcriptional activation but bind the same site of 
co-activators in a redundant manner, and when 
combined AD1 and AD2 cooperate to display 
greater than additive gene induction (19, 21, 22, 
26–28). Deletion of AD1 or AD2 in E2A abolishes 
B-lymphoid differentiation in a pre-B cell line, 
which is consistent with the observation that E2A 
plays a critical regulatory role at the earliest stages 
of B-lymphoid specification (21). The 
transcriptional regulatory role of these activation 
domains resides in their ability to recruit general 
transcriptional factors and coactivators, such as 
TFIID and the histone acetyltransferases SAGA, 
GCN5, PCAF, the paralogs CBP and p300, and 
corepressors such as ETO (19, 22, 23, 26, 29–31). 
Whereas AD3 allows the E-proteins to recruit 
TFIID to the core promoter by binding the TAFH 
domain of TAF4 (19), both AD1 and AD2 interact 
with CBP/p300 to enhance the acetyltransferase 
activity of this cofactor (26–28, 32). A conserved 
region within AD1 called the ‘p300/CBP and ETO 
target in E proteins’ (PCET) motif, is also the target 
of the transcriptional repressor ETO, and 
competition between ETO and CBP/p300 for 
binding to the PCET motif has been proposed to be 
the mechanism underlying E-protein mediated 
transcriptional silencing (31). 
CBP/p300 are multimodular proteins in which 
several protein-protein interaction domains allow 
recruitment to enhancers and promoters via 
interactions with the activation domains of an array 
of transcription factors (Fig. 1A) (33–35). AD1 and 
AD2 of the E-proteins have been reported to bind 
the same surface of the KIX domain of CBP/p300 
via their Φ-x-x-Φ-Φ sequences (where Φ represents 
a hydrophobic amino acid and x any other amino 
acid), which comprise the core PCET motif (Fig. 
1B). This interaction has been shown to be 
particularly important for leukemia induction by the 
oncogenic protein E2A-PBX1 that arises from a 
t(1;19) chromosomal translocation (20, 27, 28). In 
addition to the KIX domain, the TAZ1 and TAZ2 
domains of CBP/p300 have been shown to bind 
activation domains of several transcription factors, 
including B-Myb, C/EPBε, FOXO3a, HIF-1α, p53, 
p63, p73, STAT1, and STAT2; many of which also 
contain Φ-x-x-Φ-Φ sequences (Fig. 1B) (36–47). 
Furthermore, several activation domains have 
displayed binding promiscuity to the KIX, TAZ1, 
and TAZ2 domains presenting the opportunity for a 
multivalent mode of binding with transcription 
factors comprising multiple activation domains; 
with p53 representing the archetypical example (33, 
38, 48, 49). Despite functional roles for the three 
activation domains being attributed to the 
transcriptional activity of E-proteins, their 
interactions with CBP/p300 have not been fully 
explored.  
Here, we characterize a direct interaction 
between E2A-AD1 and the TAZ2 domain of 
CBP/p300, and elucidate the structure of a E2A-
AD1(1-37):TAZ2 complex by NMR spectroscopy. 
The structure shows residues throughout and 
adjacent to the helical PCET motif of E2A-AD1 
interact with the TAZ2 domain in a manner 
reminiscent of activation subdomain 2 (AD2) of 
p53. Peptide microarray and mutagenesis revealed 
the requirement of both hydrophobic and 
electrostatic interactions in complex formation. 
These results provide a mechanistic rational for the 
cooperative manner in which the AD1 and AD2 
domains of E2A induce gene expression.  
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Results 
TAZ2 domain of CBP/p300 binds AD1 of E2A 
Towards identifying which domains of 
CBP/p300 interact with E2A, and in particular its 
three activation domains (i.e., AD1, AD2, AD3), an 
in vitro pulldown experiment was performed 
involving GB1-E2A fusion constructs that spanned 
the entire transactivation region of E2A (residues 1-
483; Fig. 2 and S1). The KIX domain of CBP/p300 
interacted modestly with E2A-AD1, and a 
significant interaction with E2A(1-483) was 
observed, which is consistent with previous studies 
((26–28); Fig. 2). E2A did not significantly interact 
with TAZ1, but displayed a more pronounced 
ability to pulldown the isolated TAZ2 domain, as 
indicated by the corresponding protein bands from 
pulldowns with E2A-AD1, E2A-AD2 and E2A(1-
483) (Fig. 2). A quantitative assessment of the 
E2A:TAZ2 interaction by isothermal titration 
calorimetry indicated that the TAZ2 domain 
displayed a higher affinity for E2A-AD1 (i.e., 
dissociation constant (Kd) of 0.86 ± 0.04 μM) than 
for E2A-AD2 (Kd of 67 ± 7 μM), and that the former 
occurred with a 1:1 stoichiometric ratio (Fig. S2).  
Analysis of the E2A-AD1 interaction with 
TAZ2 by NMR spectroscopy revealed poor 
dispersion of the backbone amide resonances of 
uniformly 15N-labeled E2A-AD1, which suggests 
that E2A is intrinsically disordered (Fig. 3A). 
Secondary structure propensity (50) analysis  
indicated that while E2A-AD1 is largely 
disordered, residues Lys14-Met25 have elevated 
SSP scores between 0.1 and 0.35, suggesting that 
this region has residual α-helical structure (Fig. S3). 
Addition of saturating amounts of unlabeled TAZ2 
domain caused chemical shift changes and 
increased spectral dispersion, in particular for the 
backbone amide groups of residues Lys14-Phe26 
and Leu94 of E2A-AD1 (Fig. 3A insert and S4). 
Isothermal titration calorimetry measured the 
dissociation constants of TAZ2 binding for E2A-
AD1 and E2A-AD1(1-37) to be 0.86 ± 0.04 μM and 
4.1 ± 1.2 μM, respectively (Fig. S2). This is 
consistent with the chemical shift perturbation data 
of E2A-AD1, which indicates that the key TAZ2 
interacting region of E2A-AD1 lies within E2A-
AD1(1-37), while minor contributions from 
elsewhere in E2A-AD1 may lead to increased 
TAZ2 binding affinity for E2A-AD1 compared to 
E2A-AD1(1-37).  
The interaction of E2A-AD1(1-37) with TAZ2 
was further characterized by NMR spectroscopy 
because it is more feasible to characterize smaller 
proteins. Similar to what was observed for E2A-
AD1, addition of saturating amounts of unlabeled 
TAZ2 domain to 15N labeled E2A-AD1(1-37) 
caused large chemical shift changes and increased 
spectral dispersion for resonances corresponding to 
the backbone amide groups of Lys14-Phe26 (Fig. 
3B; red vs. black spectra). Chemical shift analysis 
of backbone 1H, 13C, and 15N chemical shifts of free 
and TAZ2-bound E2A-AD1(1-37) suggest that 
Asp13-Met25 undergo a random coil to α-helix 
structural change upon TAZ2 binding (Fig. S5). 
Steady-state {1H}-15N heteronuclear NOE analysis 
further indicated that when bound to the TAZ2 
domain, E2A-AD1(1-37) adopted a more ordered 
structure between Lys14 and Leu28 (i.e., {1H}-15N 
NOE values > 0.4) while the preceding N-terminal 
residues and the seven C-terminal residues 
displayed reduced {1H}-15N NOE values suggestive 
of a disordered conformation in solution (Fig. 3C).  
 
Structure of the E2A-AD1(1-37):TAZ2 complex 
To investigate the molecular basis of the E2A-
AD1(1-37):TAZ2 interaction, the structure of this 
complex was determined by NMR spectroscopy 
using 3408 NOE-derived distance restraints, 
including 197 intermolecular distance restraints, 
and 163 TALOS+ derived dihedral restraints. 
Structures were calculated from automated distance 
restraint weighting and assignment through 
CYANA and water refinement with CNS (51–53). 
The final ensemble of 20 low-energy structures of 
the 1:1 complex was well defined (Fig. 4A) and 
displayed good overall structural statistics (Table 
1), with root mean square deviation (r.m.s.d.) 
values of the ensemble core (E2A-AD1(1-37) 
residues Asp13-Pro29 and TAZ2 residues Ser1726-
Lys1812) from the energy-minimized average 
structure for the backbone and heavy atoms of 0.51 
± 0.06 Å and 0.83 ± 0.06 Å, respectively.  
The E2A-AD1(1-37) adopted an α-helix 
comprising amino acid residues Gly11-Phe26 while 
Pro27-Pro29 formed a short extended region (Fig. 
4). The ten N-terminal amino residues (Met1-
Val10) and eight C-terminal residues (Val30-
Pro37) remained disordered, flexible, and did not 
appreciably contact the TAZ2 domain, as indicated 
by the reduced {1H}-15N NOE values (Fig. 3C) and 
lack of identifiable medium- and long-range NOEs. 
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When compared to the structure of HEB-AD1 
bound to the KIX domain (27), E2A-AD1(1-37) 
was extended by one helical turn at the N-terminus 
(residues Gly11-Lys14).  
The TAZ2 domain comprised four α-helices 
(α1: Pro1727-Gln1747; α2: Pro1756-Lys1769; α3: 
Pro1780-His1795; α4: Pro1804-Lys1810) 
separated by loops (Fig. 4), each of which adopted 
a HCCC type Zn2+-coordinating conformation (54). 
Overall, the TAZ2 fold in the presence of E2A-
AD1(1-37) described here was similar to that 
previously observed for this domain when bound to 
other proteins, including the E1A oncoprotein 
(backbone r.m.s.d of 1.9 Å), isolated p53-AD1 and 
-AD2 (backbone r.m.s.d. of 2.4 Å and 2.0 Å, 
respectively), the N-terminal region of p53 
comprising both ADs (backbone r.m.s.d. of 1.8 Å), 
STAT1-AD (backbone r.m.s.d. of 1.5 Å), p63 
(backbone r.m.s.d. of 2.0 Å) and p73 (backbone 
r.m.s.d. of 1.9 Å) (38, 39, 41, 42, 44, 47). 
 
E2A-AD1:TAZ2 interface 
The E2A-AD1 interactive surface on the TAZ2 
domain involved a hydrophobic groove bounded by 
basic residues and covered ~1260 Å2 of solvent 
accessible surface area (Fig. 5A,B). The 
hydrophobic groove comprised the aliphatic region 
of Arg1732, Ile1735 and Ala1738 of α1, the 
aliphatic region of Lys1760, Met1761 and Val1764 
of α2, and Pro1780, Ile1781, Gln1784, Leu1785, 
Leu1788 and Tyr1791 of α3 (Fig. 5C). Residues 
throughout the helical region of E2A-AD1, 
including Leu19, Phe22, Met25 and Phe26, and the 
residues Pro27 and Leu28 C-terminal to the helix 
made extensive non-polar contacts with the TAZ2 
domain (Fig. 5D). Within the E2A-AD1 helix, the 
side chain of Leu19 inserted into a cavity formed by 
Val1764, Pro1780, Ile1781, the aliphatic region of 
Gln1784, and Leu1785. The aromatic side chain of 
Phe22 from E2A-AD1 participated in van der 
Waals contacts with the aliphatic portion of 
Lys1760, Met1761, and Val1764. Met25 interacted 
with Ala1738 and Leu1788 while Phe26 associated 
with Ile1735, Ala1738, Ala1787, Leu1788, and the 
aliphatic region of Gln1784. Beyond the helical 
region of E2A-AD1, Pro27 formed non-polar 
contacts with Ile1735 while Leu28 resided in 
hydrophobic pocket created by aliphatic region of 
Arg1732, Ile1735, Leu1788, and Tyr1791 of the 
TAZ2 domain.  
Several electrostatic and hydrogen bonding 
interactions involving residues in the helical region 
of E2A-AD1 complemented the extensive non-
polar network at the E2A-AD1:TAZ2 interface. 
Glu15 of E2A-AD1 was situated to form a salt 
bridge with His1767 of α2 of TAZ2 (dOε*-Nδ1 = 3.6 
± 0.4 Å). Asp18 was positioned to participated in 
salt bridges with both Lys1760 (dOδ*-Nζ = 3.1 ± 0.5 
Å) and Arg1763 (dOδ2-Nε = 4.5 ± 1.5 Å) while Asp21 
was also in close proximity to Lys1760 of TAZ2 
(dOδ*-Nζ = 3.6 ± 0.9 Å). 
 
Mutants traversing the helical region of E2A-
AD1 attenuate TAZ2 binding 
To assess the relative contribution of each 
residue of E2A-AD1 in TAZ2 recognition, the 
effect of E2A-AD1 alanine mutants were assessed 
by peptide microarray and isothermal titration 
calorimetry (Fig. 6). For the peptide microarray, 
HEB-AD1(11-28) peptides (which is identical to 
E2A-AD1 except for a Met24 to Ala substitution), 
in which each position was individually substituted 
to alanine, were probed with recombinant His6-
GB1-TAZ2 (Fig. 6A). Compared to wild-type 
HEB-AD1(11-28), alanine substitutions at Leu19 
and Phe22 led to significantly reduced signal while 
substitutions at Leu16, Asp18, and Asp21 modestly 
reduced the signal. Complementary quantitative 
analysis by isothermal titration calorimetry 
indicated that the Leu19Ala and Phe22Ala 
substitutions both resulted in a ~4-fold reduction in 
affinity (Kd of 17 μM and 16 μM, respectively) (Fig. 
6B). Thus, while no single point mutation of E2A-
AD1 completely abrogates TAZ2 binding, the 
E2A-AD1(1-37):TAZ2 structure, peptide 
microarray, and isothermal titration calorimetry 
indicate that L19 and F22 are key binding elements 
of the interaction. 
 
KIX and TAZ2 of CBP/p300 compete for E2A-
AD1 
The orientation of E2A-AD1 on the TAZ2 
surface presented the possibility of a higher-order 
interaction with the KIX domain of CBP/p300 as 
several of the KIX-interactive residues, including 
the critical Leu20 (20), were solvent exposed; a 
scenario supported by the recent observation that 
full-length CBP/p300 displays intrinsic 
conformational flexibility (33, 55). To directly 
assess the formation of such a complex or whether 
KIX and TAZ2 displayed exclusive E2A-AD1 
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binding, an NMR-based displacement experiment 
was performed. Addition of unlabeled E2A-AD1(1-
37) to uniformly 15N-labeled KIX resulted in 
significant chemical shift changes for a subset of 
backbone amide resonances in 15N-KIX spectra 
(Fig. 7A), consistent with the site-specific binding 
of E2A-AD1(1-37) to KIX (27). Subsequent 
addition of unlabeled TAZ2 to the sample caused 
those backbone resonances of uniformly 15N-
labeled KIX to revert back towards chemical shift 
values consistent with the free form of the KIX 
domain (Fig. 7B). These results indicate that the 
TAZ2 and KIX domains of CBP/p300 can only 
interact with E2A-AD1 exclusive of one another. 
 To further investigate a higher-order interaction 
between CBP and E2A, a pulldown experiment 
involving GB1-E2A(1-483) constructs and full-
length FLAG-tagged CBP was performed and 
visualized using an anti-FLAG western blot (Fig. 8 
and S6). Compared to wild-type, alanine 
substitutions in the AD1 region of E2A(1-483) that 
disrupt either TAZ2 binding, (Leu19Ala and 
Phe22Ala) or KIX binding (Leu20Ala; (20)) 
significantly reduced the ability of E2A(1-483) to 
pulldown CBP. An alanine and proline substitution 
in AD2 of E2A(1-483) that disrupts KIX binding 
(Leu397Ala/Ile401Pro; (28)) similarly displayed 
reduced pulldown of flag-CBP. Mutations in both 
AD1 and AD2 of E2A(1-483) were required to 
abrogate any observable interaction between GB1-
E2A(1-483) and CBP. 
 
Discussion 
The E2A activation domains are essential for 
lymphopoiesis and are involved in the onset of ALL 
through the oncogenic fusion protein E2A-PBX1 
(56). In either situation, the recruitment of 
CBP/p300 is essential for E2A or E2A-PBX1 
function. Here we investigate recruitment of 
CBP/p300 by E2A-AD1, which provides insight 
into the molecular mechanisms underlying 
lymphopoiesis and ALL.  
Depending on the context, the activation 
domains of E2A function independently, 
redundantly, or cooperatively with each other (19, 
21–28, 57). The KIX domain of CBP/p300 binds 
both E2A-AD1 and E2A-AD2 in a functionally 
redundant manner, with both E2A-AD1 and E2A-
AD2 competing for the same site of KIX (27, 28). 
The additional interactions of TAZ2 with E2A-
AD1 or E2A-AD2 that we describe (Fig. 2 and S2) 
raise the possibility that both AD1 and AD2 could 
simultaneously interact with the KIX and TAZ2 
domains to allow for higher affinity association 
between CBP/p300 and E2A. This possibility is 
supported by our pulldowns of full-length CBP 
(Fig. 8), where intact AD1 and AD2 were required 
for maximum CBP/p300 pulldown and mutations in 
either the AD1 or AD2 region lessened the 
interaction by ~50%. It is unclear what the binding 
preferences of E2A-AD1 and E2A-AD2 are to full 
length CBP since E2A-AD1 and E2A-AD2 are able 
to bind both the KIX and TAZ2 domains. The 
ability of E2A to form a tight yet dynamic complex 
with CBP through multiple weaker interactions is 
likely essential for its transcriptional activity and 
provides rationale for how deletion of AD1 or AD2 
abolishes B-lymphoid differentiation (21). This is 
reminiscent of p53, which also associates with 
multiple domains of CBP/p300 to form a tight, yet 
dynamic, complex (49). 
The promiscuous interactions of intrinsically 
disordered proteins are recognized as key to their 
roles as protein interaction hubs (33, 58). This 
appears to be the case with E2A since E2A-AD1 
and its nearly identical homologue HEB-AD1 (Fig. 
1B) can complement and bind a variety of 
molecular surfaces, with high-resolution structures 
available of the KIX:HEB-AD1 and eTAFH:HEB-
AD1 complexes. HEB-AD1 adopts an amphipathic 
α-helix from Lys14-Phe26 (renumbered according 
to the E2A sequence) when bound to KIX, a kinked 
α-helix spanning residues Asp13-Leu20 and Ser23-
Phe26 when bound to eTAFH, and E2A-AD1 
adopts an amphipathic α-helix from Asp13-Met25 
when bound to TAZ2. Leu16, Leu19, and Leu20 
form essential hydrophobic contacts with both 
eTAFH and KIX (27, 59), while Phe22 forms 
additional hydrophobic contacts with KIX and 
TAZ2 but not eTAFH. Although the entire PCET 
motif is involved in recognition of eTAFH, KIX, 
and TAZ2, Phe26, Pro27 and Leu28 have 
additional hydrophobic contacts to TAZ2. Finally 
eTAFH, KIX, and TAZ2 have basic residues 
situated nearby the E2A-AD1 binding site, 
providing unique potential electrostatic contacts for 
Glu15, Asp18 and Asp21. The different modes of 
E2A-AD1 binding to eTAFH, KIX, and TAZ2 are 
highlighted by the importance of Leu20, which is 
essential for the HEB:KIX, and HEB:eTAFH 
interactions (27, 59), but dispensable for binding to 
TAZ2 as it is facing solvent and alanine 
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substitutions are non-perturbing to a pulldown 
experiment (Fig. 5 and 6).  
The TAZ2 domain of CBP/p300 is promiscuous 
and interacts with many intrinsically disordered 
proteins, with structures available for TAZ2 in 
complex with activation domains from E1A, 
C/EBPε, p53, p63, p73, and STAT 1 (36, 38, 39, 41, 
42, 47). Highlighting the promiscuity of the TAZ2 
domain, E1A, p73, and STAT 1 bind TAZ2 in part 
to a hydrophobic groove formed by α1, α2, and α3, 
while p53, p63, and E2A-AD1 adopt an α-helical 
structure when they bind to this same region of 
TAZ2 (Fig. 9). The adenoviral protein E1A has 
been shown to decrease E2A transcriptional activity 
(60) and the observation that E2A-AD1 and E1A 
bind overlapping sites of TAZ2 suggests that E1A 
inhibits E2A function through direct competition 
for TAZ2. Interestingly, although E2A-AD1, p53, 
and p63 bind the same region of TAZ2 as an α-
helix, the peptides have differing orientations (Fig. 
9 and 10). Despite the opposite orientations of p53 
and E2A-AD1, Phe22 and Phe26 of E2A-AD1 
occupy similar positions as Phe54 and Ile50, 
respectively (Fig. 10). These residues all face 
TAZ2, suggesting that an amphipathic helix is key 
for binding to the α1, α2 and α3 binding surface of 
TAZ2. The importance of these hydrophobic 
residues is confirmed by our mutagenesis studies in 
which mutation of Phe22 or Phe26 to alanine 
decreased the signal observed in a microarray, 
while mutation of I50 and Phe54 of p53 weakens 
binding of p53-AD2 to TAZ2 by approximately 3 
fold and 2 fold, respectively (44). Other than the 
presence of a Φ-x-x-Φ-Φ sequence and being acidic 
with some hydrophobic residues, the sequences of 
TAZ2-binding activation domains are quite 
divergent and TAZ2 appears to be able to 
accommodate a variety of peptide sequences, 
orientations, and secondary structure content. 
The orientation of an amphipathic α-helix bound 
to TAZ2 likely depends on the specific interactions 
of polar residues and neighbouring sequences with 
TAZ2. For E2A-AD1 Asp18 and Asp21 are likely 
involved in a salt bridge to the sidechain of Lys1760 
(Nζ – Oδ distance of 3.1 ± 0.53 Å and 3.6 ± 0.9 Å, 
respectively), while Phe26, Pro27 and Leu28 all 
participate in further hydrophobic contacts to 
TAZ2. For p53 a similar situation occurs where 
Glu11 and Glu17 contact the guanidinium group of 
Arg1731 and multiple other residues engage in 
specific polar contacts to TAZ2 (41). In support of 
this, substitution of Asp18 and Asp21 with alanine 
decreases TAZ2 binding in a peptide microarray 
(Fig. 6). Given that acidic residues influence E2A-
AD1 affinity for TAZ2, phosphorylation of E1A 
(e.g. at Thr12, Ser17 and Ser23) may enhance the 
affinity of E2A-AD1 to TAZ2 by forming salt 
bridges to nearby basic residues of TAZ2. A similar 
situation has been observed with p53, which has a 
graded enhancement of affinity for CBP/p300 upon 
phosphorylation (61). Overall, TAZ2 is able to 
accommodate a wide variety of peptides through a 
complex interplay of hydrophobic and electrostatic 
interactions, and phosphorylation may be a 
common method to regulate protein association 
with TAZ2.  
 
Experimental procedures 
Plasmid preparation. All constructs were cloned 
into a pET21a(+) vector using BamHI and XhoI 
restriction enzymes downstream of sequences 
coding for a hexahistidine (His6) tag, the B1 domain 
of protein G (GB1) and either a thrombin (human 
E2A(1-37) (hereafter referred to as E2A-AD1(1-
37)), CBP(346-440) (TAZ1), and p300(1723-1812) 
(TAZ2)) or TEV (human E2A(1-100) (E2A-AD1), 
E2A(101-300) (E2A-AD3), E2A(301-483) (E2A-
AD2), and E2A(1-483)) protease recognition 
sequence. A modified TAZ2 construct in which 
cysteine residues not involved in zinc coordination 
were substituted for alanine (i.e., Cys1738Ala, 
Cys1746Ala, Cys1789Ala, Cys1790Ala) was 
generated based on its reported enhanced stability 
(41, 54). E2A-AD1(1-37) mutants were generated 
using the QuikChange site-directed mutagenesis kit 
(Stratagene), with His6-GB1-E2A-AD1(1-37) as a 
template. E2A(1-483) mutagenesis was performed 
using QuikChange II site-directed mutagenesis kit 
(Agilent Technologies, 200523) with His6-GB1-
E2A(1-483) as a template. The fidelity of all 
constructs was verified by DNA sequencing. 
Plasmids were subsequently transformed into 
Escherichia coli BL21(DE3) cells for recombinant 
protein expression. 
 
Protein expression and purification. The isolated 
KIX domain (residues 586-673 of CBP) was 
expressed and purified as previously described 
(27). E. coli BL21(DE3) cells harbouring the His6-
GB1-TAZ1 and His6-GB1-TAZ2 encoding 
plasmids were grown in LB or 15N- or 13C/15N-
enriched M9 media at 37°C supplemented with 100 
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μM ZnCl2. Protein expression was induced at 
optical density of 0.6 at 600 nm by adding isopropyl 
β-D-1-thiogalactopyranoside (IPTG) to a final 
concentration of 0.5 mM. Growth was continued 
overnight at 23°C with shaking. Harvested cell 
pellets were lysed by sonication in denaturing 
binding buffer (20 mM Tris-HCl pH 8.0, 250 mM 
NaCl, 8 M urea, 10 mM β-mercaptoethanol, 10 µM 
ZnCl2), clarified by centrifugation, and applied to 
Ni2+-affinity resin (GE Healthcare). Upon extensive 
washes with denaturing binding buffer containing 
10 mM imidazole, protein constructs were refolded 
on-column by application of native Ni2+ binding 
buffer (20 mM Tris-HCl pH 8.0, 250 mM NaCl, 10 
mM β-mercaptoethanol, 10 µM ZnCl2), and 
subsequently eluted in the same buffer containing 
300 mM imidazole. The elution fractions were 
pooled, and β-mercaptoethanol and ZnCl2 were 
added to final concentrations of 40 mM and four-
fold excess relative protein, respectively. 
Thrombin, at 1 unit per 50 nanomoles of protein, 
was added and the samples were dialyzed overnight 
in buffer A (20 mM HEPES pH 8.0, 50 mM NaCl, 
5 mM β-mercaptoethanol, 10 µM ZnCl2). The 
cleaved, refolded TAZ1 or TAZ2 constructs were 
separated from the His6-GB1 fragments via fast 
flow SP sepharose cation chromatography (GE 
Healthcare) using buffer A as a wash buffer, and 
eluted with buffer A containing 500 mM NaCl.  
Expression of all His6-GB1-E2A constructs 
were induced in transformed E. coli BL21(DE3) 
cells with 0.5 mM IPTG at an optical density of ~1 
at 600 nm. Growth was continued for an additional 
4 hours at 37°C with shaking. Expression of His6-
GB1-E2A(1-483) L397A/I401P mutants was 
performed as described except that after induction 
with IPTG, growth was continued for an additional 
16 hours at 23°C with shaking. Purification of His6-
GB1-E2A(1-483), E2A-AD1, and E2A-AD2 was 
performed as described above for the TAZ 
domains, with the exception that ZnCl2 was 
excluded from all buffers. Purification of wild-type 
and mutant E2A-AD1(1-37) constructs was 
performed as previously described (28).  
For uniformly 13C- and/or 15N-labeled NMR 
samples high performance liquid chromatography 
was used to purify TAZ2 or E2A-AD1(1-37) on a 
C18 reverse phase column with a water:acetonitrile 
gradient with 0.05% trifluoroacetic acid. Fractions 
containing protein were pooled, lyophilized, and 
stored at -20°C. The integrity of each protein 
sample was verified by SDS-PAGE analysis, mass 
spectrometry, and NMR spectroscopy. 
 
In vitro pulldown experiments. His6-GB1, His6-
GB1-E2A-AD1, His6-GB1-E2A-AD3, His6-GB1-
E2A-AD2, and His6-GB1-E2A(1-483) were 
incubated with 20 µL of 50% IgG agarose slurry 
(GE Healthcare) for 15 minutes in assay buffer (20 
mM MES pH 6.5, 100 mM NaCl). After 2 washes 
with assay buffer, 1 mL of 20 μM KIX, TAZ1 or 
TAZ2 was added to the beads and left for 30 
minutes with gentle agitation. After incubation, the 
beads were washed three times with assay buffer 
and resuspended in SDS-PAGE loading buffer. 
KIX, TAZ1, and TAZ2 binding to the His6-GB1-
E2A constructs were visualized using SDS-PAGE. 
For TAZ1 pulldown experiments, the assay buffer 
included 5 mM β-mercaptoethanol and for TAZ2 
pulldown experiments, the assay buffer included 5 
mM β-mercaptoethanol and 10  µM ZnCl2. All 
experiments were done in duplicate. 
 
Cell culture and cell lysis. HEK 293T cells were 
seeded at 0.8 x 106 cells per well in a 6-well culture 
plate. The following day, the cells were transfected 
with 2 ug of a flag-CBP plasmid using jetPRIME 
transfection reagent (Polyplus, 114-01) according 
to the manufacturers protocol. After 24 hours, the 
transfection medium was exchanged for cell growth 
medium. Following 48 hours after transfection, the 
cells were washed twice with PBS and lysed for 10 
minutes at room temperature with gentle agitation 
in NP-40 buffer (50 mM Tris pH 8.0, 150 mM 
NaCl, 1.0% NP-40) plus protease inhibitors 
(Thermo Fisher Scientific, A32965). The lysates 
were sonicated briefly and clarified by 
centrifugation. 
 
Immunoblotting. In vitro pulldown experiments 
were performed as described above with the 
following modifications: i) His6-GB1 and His6-
GB1-E2A(1-483) wild-type and mutant constructs 
were incubated with 5 uL of 50% IgG agarose 
slurry (GE Healthcare) for 30 minutes in NP-40 
buffer, ii) 250 uL of flag-CBP transfected HEK 
293T cell lysate was added to the beads and left for 
3 hours with gentle agitation, iii) all washes were 
done with NP-40 buffer. The pull-down 
experiments were loaded onto 6% Tris-glycine gels 
and separated by SDS-PAGE. The proteins were 
transferred to nitrocellulose membranes using Bio-
  Characterization of the E2A-AD1:TAZ2 complex 
 8 
Rad wet electroblotting system for 16 hours at 20 V 
at 4°C. Membranes were blocked for 1 hour at room 
temperature with 5% skimmed milk in Tris-
buffered saline plus 0.1% Tween 20 (TBST) and 
subsequently incubated for 1 hour at room 
temperature with horse radish peroxidase-
conjugated α-FLAG antibody (Sigma Aldrich, 
A8592) diluted 1:5000 in TBST. Membranes were 
then washed four times with TBST, stained with 
Immobilin Forte Western HRP substrate (EMD 
Millipore, WBLUF0100), and exposed to X-ray 
films. The pull-down experiments and 
immunoblotting were performed in triplicate and 
ImageJ was used to quantify the X-ray films.  
  
Isothermal titration calorimetry. Experiments 
were carried out at 30°C in 20 mM MES pH 6.5, 5 
mM β-mercaptoethanol and 10 µM ZnCl2, using 
100-200 µM TAZ2 in the cell and 1-2 mM E2A 
construct in the syringe (E2A-AD1, E2A-AD2, 
E2A-AD1(1-37), E2A-AD1(1-37)L19A, or E1A-
AD1(1-37)F22A). Experiments were performed on 
VP-ITC or iTC200 calorimeters (MicroCal). 
Thermograms were fit to a one-site binding model 
using MicroCal Origin 7.0 software. All 
experiments were collected in at least duplicate. 
 
Peptide microarray. Peptide microarrays were 
synthesized through automatic SPOT synthesis 
with a MultiPep automated peptide synthesis 
system (Intavis) using 9-
fluorenylmethyloxycarbonyl chemistry (62). HEB-
AD1 derived peptides were synthesized onto 
continuous cellulose membranes to generate strip 
arrays, which were hydrated with ethanol, washed 
with assay buffer (50 mM Tris-HCl pH 7.4, 150 
mM NaCl) and blocked overnight in assay buffer 
containing 2% milk. Following washes with assay 
buffer containing 0.5% Tween 20, the arrays were 
incubated for 4 hours with 5-10 µg/mL His6-GB1-
TAZ2 in 50 mM Tris-HCl pH 7.4, in assay buffer 
containing 2% skim milk, washed with assay 
buffer, and incubated for 1 hour with rabbit 
polyclonal antibody against the His6 tag conjugated 
to horse radish peroxidase (Abcam) diluted in assay 
buffer containing 2% skim milk. After a final wash 
with assay buffer, luminata horseradish peroxidase 
substrate (Millipore) was applied to the arrays and 
X-ray film was used to detect the signal. 
 
NMR spectroscopy and structure calculation. 
Lyophilized recombinant TAZ2 was reconstituted 
for NMR studies as previously described (54). For 
the assignment of E2A-AD1, a 1 mM sample of 
13C/15N labeled E2A-AD1 in 20 mM MES, 50 mM 
NaCl, and 5% D2O adjusted to pH 6.5 was 
prepared, and data was collected at 25°C. For 
structural analysis of the E2A-AD1(1-37):TAZ2 
complex, two samples were prepared containing 
either 1 mM uniformly 13C/15N-labeled TAZ2 with 
3 mM E2A-AD1(1-37) or 2 mM TAZ2 with 1.4 
mM uniformly 13C/15N-labeled E2A-AD1(1-37) in 
20 mM MES, 5 mM β-mercaptoethanol, 100 µM 
ZnCl2 and 5% D2O adjusted to pH 6.5 without 
accounting for deuterium isotope effects. 
Resonance assignments of E2A-AD1, E2A-AD1(1-
37), and TAZ2 were carried out using standard 
multi-dimensional heteronuclear NMR 
experiments. Distance restraints for the E2A-
AD1(1-37):TAZ2 complex were determined using 
3D 15N-NOESY-HSQC and both aliphatic and 
aromatic 13C-NOESY-HSQC experiments, all with 
a 100 ms mixing time. The validity of 
intermolecular restraints was confirmed using 
12C/14N-filtered 15N-edited and 12C/14N-filtered 13C-
edited NOESY spectra. All NMR experiments 
involving E2A-AD1(1-37) were collected at 15°C 
on 500, 600 or 800 MHz Varian INOVA 
spectrometers equipped with triple resonance 
cryoprobes. NMR data were processed using 
NMRPipe (63) and analyzed using CCPNMR 
Analysis (64). 
NOESY peaks lists were exported from 
CCPNMR Analysis and used in CYANA for 
automatic NOE assignment and distance restraint 
calibration (52, 53). Dihedral angle restraints based 
on chemical shifts were generated using TALOS+, 
with angle error set to two times the error output of 
TALOS+ (65). After confirming a correct TAZ2 
fold using only NOE-based distance and dihedral 
angle restraints, hydrogen bond restraints (1.8 ≤ dOH 
≤ 2.2 Å; 2.7 ≤ dON ≤ 3.2 Å) were applied to helical 
regions of the E2A-AD1(1-37):TAZ2 complex 
while zinc coordination restraints were applied to 
known Zn2+ coordinating residues (54). Using 
CYANA, an initial ensemble of the lowest energy 
20 models was retained from 100 generated models. 
These 20 models were further energy minimized in 
explicit water using fmcGUI and CNS (51). The 
final ensemble of 20 models was validated using 
PROCHECK-NMR (66) and the recall, precision, 
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F-measure and discriminating power scores of the 
final ensemble of the E2A-AD1(1-37):TAZ2 
complex were calculated using CCPNMR Analysis 
(64, 67). The protein structure validation software 
suite was used to determine the ordered residues 
and evaluate the quality of the final E2A-AD1(1-
37):TAZ2 ensemble (68). The ensemble of 20 
lowest-energy structural models was deposited to 
the Protein Data Bank (accession no. 2MH0) while 
1H, 13C, and 15N chemical shifts and restraints were 
deposited to the BMRB (accession no: 19610). 
For the NMR-based experiment assessing the 
ability of TAZ2 and KIX to compete for binding to 
E2A-AD1 a sample of 200 µM 15N-labeled KIX 
and 300 µM unlabeled E2A-AD1(1-37)  in 20 mM 
MES pH 6.8, 5 mM β-mercaptoethanol, 10 μM 
ZnCl2, 95% H2O/5% D2O was used. Unlabeled 
TAZ2 was subsequently added to the sample to a 
final concentration of 500 µM.  
 
Accession codes. Chemical shift assignments for 
the E2A-AD1(1-37):TAZ2 complex and E2A-
AD1 have been deposited in the BioMagResBank 
(accession numbers 19610 and 50196, 
respectively). The atomic coordinates (accession 
code 2MH0) have been deposited in the Protein 
Data Bank. 
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Table 1. Structural statistics of the E2A-AD1:TAZ2 complex. 
Distance restraints used for structure calculations AD1 TAZ2 
Intra Residue 172 621 
Sequential ( l i-j l = 1) 290 722 
Medium Range (1< l i-j l <5) 222 774 
Long Range ( l i-j l≥5) 1 409 
Intermolecular 197 
Total 3408 
Hydrogen bond restraints 10 44 
Dihedral Restraints  
φ 14 67 
ψ 14 68 
Energies (kcal mol-1) 
Total -3328 ± 93 
Van der Waals -758 ± 12 
RMSD from experimental restraints  
Distance constraints (Å) 0.021 ± 0.002 
Dihedral angles (°) 0.418 ± 0.088 
RMSD from idealized geometry  
Bond lengths (Å) 0.015 ± 0.001 
Bond angles (°) 0.973 ± 0.013 
Global quality scores (Raw/Z-score) 
Verify3D 0.33/-2.09 
Procheck (phi-psi) -0.17/-0.35 
Procheck (all) -0.33/-1.95 
MolProbity clash score 16.88/-1.37 
RPF Validation  
     Recall 0.906 
Precision 0.872 
F-measure 0.889 
Discriminating power 0.807 
Ramachandran statistics (%)1  
Residues in most favoured regions 94.4 
Residues in additionally allowed regions 4.6 
Residues in generously allowed regions 0.2 
Residues in disallowed regions 0.9 
RMSD to mean structure (Å)1   
Backbone atoms  0.51 ± 0.06 
Heavy atoms  0.83 ± 0.06 










Figure 1. Domain architecture of E2A and CBP/p300. (A) Schematic representation of E2A and the 
human histone acetyltransferase (HAT) p300, with the relevant domains (E2A: activation domains AD1, 
AD2, and AD3 and the C-terminal DNA-binding basic helix-loop-helix (bHLH) domain; p300: The 
TAZ1, KIX, and TAZ2 protein-protein interaction domains and the HAT catalytic domain) indicated. (B) 
Sequence alignment of the ϕ-x-x-ϕ-ϕ motifs of the activation domains (AD) of E2A, HEB, FOXO3a, p53, 
and p63, where ϕ represents a hydrophobic amino acid residue and x any amino acid residue. 
Hydrophobic, acidic, and basic amino acid residues are coloured yellow, red, and blue, respectively. 
Numbering is in accordance with the native protein sequence.  
 
  
Φ X X Φ Φ
E2A-AD1 10 V G T D K E L S D L L D F S M M F 26
HEB-AD1 11 I G T D K E L S D L L D F S A M F 27
FOXO3a-CR2C 464 H Y G N Q T L Q D L L T S D D L S 680
FOXO3a-CR3 618 G S L E C D M E S I I R S E L M D 634
p53-AD1 13 P L S Q E T F S D L W K L L P E N 29
p53-AD2 44 M L S P D D I E Q W F T E D P G P 60
p63 10 F L S P E V F Q H I W D F L E Q P 26
B
AD1 AD2 bHLH
1 654100 300 483
AD3
TAZ1 KIX HAT TAZ2











Figure 2. E2A-AD1 binds the TAZ2 domain of CBP/p300. (A) 15% SDS-PAGE analysis of the ability of 
various purified His6-GB1-E2A fragments immobilized on IgG agarose to pulldown purified recombinant 
KIX, TAZ1, and TAZ2 domains of p300. The left lanes of each panel represent controls illustrating the 
migration of the recombinant isolated p300 domains. (B) Quantitative analysis of the His6-GB1-E2A 
pulldowns presented in (A). Significance between pulldown protein levels of TAZ1, TAZ2 and KIX by 
GB1 (negative control) and GB1-E2A constructs is indicated by brackets. Error bars represent the 
























































































































































































Figure 3. The ϕ-x-x-ϕ-ϕ containing region of E2A-AD1(1-37) adopts an ordered structure upon TAZ2 
binding. (A) The 1H-15N HSQC of uniformly 15N-labeled E2A-AD1. Resonance assignments are indicated 
and * denotes resonances that are due to impurities or could not be assigned due to spectral overlap. The 
inset indicates the weighted chemical shift change (Δδ = [(0.17ΔδN)2 + (ΔδHN)2]1/2 that each residue of 
E2A-AD1 experiences upon addition of saturating amounts of TAZ2. (B) Overlay of 1H-15N HSQC 
spectra of uniformly 15N-labeled E2A-AD1(1-37) in the absence (black) and presence (red) of saturating 
amounts of TAZ2. Resonance assignments are indicated, and arrowed lines indicate the directional 
movement of resonances upon addition of TAZ2. Resonances attributed to impurities are indicated with *. 
(C) A plot of steady state {1H}-15N NOE values recorded at 14.1 T as a function of E2A-AD1(1-37) 
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Figure 4. Structure of the E2A-AD1(1-37):TAZ2 complex. (A) Backbone superposition of the 20 lowest-
energy structures of the E2A-AD1(1-37):TAZ2 complex, with the backbone atoms (N, Cα and C’) of 
Asp13-Pro29 of E2A-AD1(1-37) (pink) and Ser1726-Lys1812 of the TAZ2 domain (teal) displayed. (B) 
Backbone ribbon illustration of the lowest energy structure of the E2A-AD1(1-37):TAZ2 complex. The 
helices of the TAZ2 domain are labeled α1, α2, α3, and α4, and the N- and C-termini of E2A-AD1(1-37) 

























Figure 5. The E2A-AD1(1-37):TAZ2 interface. (A) Backbone ribbon representation of the lowest energy 
structure of the E2A-AD1(1-37) (pink):TAZ2 (teal) complex onto which a transparent surface 
representation of the TAZ2 domain also displayed. (B) Electrostatic surface representation of the E2A-
AD1 binding face of TAZ2 domain, where blue and red shadings depict positively and negatively charged 
regions, respectively. (C) Expanded view of transparent surface of the TAZ2 domain displaying the 
backbone ribbon and residues involved in intermolecular van der Waals contacts with E2A-AD1(1-37). 
(D) Backbone ribbon representation of E2A-AD1(1-37) (pink) showing those residues making 




























Figure 6. E2A-AD1 mutants impair TAZ2 binding. (A) Membranes spotted with HEB-AD1(11-28) 
peptides in which each residue had been individually substituted with alanine were probed with His6-
GB1-TAZ2. The sequence of HEB is indicated using E2A numbering and each position of HEB-AD1(11-
28) was mutated to alanine and spotted onto an array. The signal present from TAZ2 binding to each 
alanine mutant of HEB-AD1(11-28) is indicated as a spot below the sequence. (B) The isothermal 
titration calorimetric dissociation constants determined for the interaction between wild-type, Leu19Ala 
and Phe22Ala E2A-AD1(1-37) and the isolated TAZ2 domain. (C,D) Ribbon representation of the E2A-
AD1(1-37):TAZ2 complex with a transparent TAZ2 surface showing the position of Leu19 (C) and 
Phe22 (D) of E2A-AD1 (pink) on the TAZ2 (teal) surface.  
 
  
A Construct Dissociation constant 
(µM)
E2A-AD1(1-37) 4.1 ± 1.2
E2A-AD1(1-37) L19A 16.8 ± 1.1
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Figure 7. TAZ2 and KIX domains compete for E2A-AD1 in vitro. (A) Overlay of two selected regions 
from 2D 1H-15N HSQC spectra of 200 μM 15N-KIX in the absence (black) and presence (red) of 300 μM 
unlabeled E2A-AD1(1-37). (B) Overlay of the same two regions depicted in panel A after the addition of 
500 μM unlabeled TAZ2. The direction of backbone amide resonance change is depicted by red and green 
arrows in panels A and B, respectively. 
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Figure 8. Mutation of AD1 or AD2 of E2A(1-483) reduces its ability to pulldown CBP. (A) 
Immunoblotting of comparative pull-downs of flag-CBP by purified His6-GB1-E2A(1-483) constructs 
immobilized on IgG agarose. (B) Relative quantitative analysis of the western blots performed in 
triplicate. ImageJ was used to measure the pixel density for each lane. The y-axis values represent the 
ratio of flag-CBP pull-down by His6-GB1-E2A(1-483) mutants to flag-CBP pull-down by His6-GB1-




























































































































































Figure 9. Transcription factors adopt diverse structures and orientations when interacting with Taz2. (A) 
Backbone ribbon representation of p53 (5HPD; orange (38)), E2A-AD1(1-37) (pink), and STAT1 (2KA6; 
yellow (47)) in complex with TAZ2, which is shown as a teal surface. In (B) the binding orientations of 

















Figure 10. E2A-AD1 and p53 bind TAZ2 with opposite orientations. (A) Ribbon representation of a 
superposition of the E2A-AD1(1-37):TAZ2 and p53:TAZ2 (38) complexes, with only TAZ2 (teal), E2A-
AD1(1-37) (pink), and p53 (yellow) shown. The side chains of Phe22 and Phe26 of E2A-AD1 as well as 
Ile50 and the Phe54 of p53 are displayed as sticks. (B) A sequence alignment of E2A-AD1 and p53. The 
sequence of p53 is reversed with respect to E2A-AD1 and the residues highlighted in (a) are coloured red. 
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